A leading insurance broker has projected that employer-sponsored healthcare costs in the United States will rise by 9.5 percent next year, potentially adding significant financial pressure on businesses already managing tight operating margins.
The analysis from Aon, the second-largest global insurance broker, attributes the increase to growing specialty drug prices and continued medical trend growth. The firm released its annual health care trend forecast this week, noting that without intervention, employers could face double-digit premium increases when negotiating benefits for 2027 coverage.
What the Right Is Saying
Conservative economists and Republican lawmakers counter that regulatory mandates and government intervention in healthcare markets drive up costs for employers and consumers alike. They argue that free-market competition, reduced administrative burden, and greater price transparency would naturally constrain spending growth.
Senator Bill Cassidy of Louisiana, who serves on the Senate Health Committee, has advocated for Association Health Plans that would allow small businesses to pool resources and negotiate better rates. His office released a statement saying 'onerous regulations prevent employers from offering affordable options' and called for expanding health savings accounts to give workers more control over their healthcare spending.
The American Enterprise Institute, a conservative think tank, published analysis arguing that price controls on pharmaceuticals would stifle innovation and ultimately reduce the quality of care available. Industry groups representing insurers and employers have similarly warned that government-mandated benefit packages increase costs without improving outcomes.
What the Left Is Saying
Democratic policymakers and healthcare advocates argue that rising employer costs ultimately harm workers through higher deductibles, reduced benefits, or shifting of premiums onto employees. They point to pharmaceutical pricing as a key driver and have long advocated for government intervention to cap drug prices.
Senator Elizabeth Warren of Massachusetts said at a recent Senate hearing that 'working families are bearing the burden of pharmaceutical industry greed' and called for expanded Medicare negotiation powers to bring costs down. Progressive groups, including Families USA, have pushed for a public option or Medicare expansion to create negotiating leverage against private insurers.
Consumer advocates warn that when employers face higher health costs, workers often see reduced coverage options or increased cost-sharing. The AFL-CIO has argued that stronger price transparency requirements and caps on out-of-pocket expenses would protect employees from bearing the full impact of rising premiums.
What the Numbers Show
Aon's 2026 Health Care Trend Survey found that U.S. employer health costs are trending upward at rates exceeding general inflation, which stood at approximately 2.7 percent year-over-year as of mid-2026. The broker's analysis projects medical trend growth of 9.5 percent for 2027, compared to an actual increase of 8.3 percent in 2025.
Specialty medications, particularly those used to treat complex conditions such as autoimmune disorders and cancer, represent a disproportionate share of spending growth. Aon estimates that specialty drugs now account for roughly 50 percent of total pharmacy costs for large employers despite representing fewer than 2 percent of prescriptions by volume.
According to the Kaiser Family Foundation's 2025 Employer Health Benefits Survey, the average annual premium for family coverage reached $24,572, with employees contributing an average of $6,296 toward that cost. Small businesses consistently face higher per-employee costs than large firms, a disparity often attributed to reduced negotiating leverage and greater regulatory complexity.
The Bottom Line
The projected 9.5 percent increase in employer health costs reflects ongoing pressures from specialty drug pricing and utilization growth that have persisted for years without clear resolution. How employers respond will likely vary based on company size, workforce demographics, and industry sector.
Some businesses may absorb the higher costs to remain competitive in talent acquisition, while others could shift more premium responsibility to workers or reduce benefit breadth. Watch for how companies report healthcare expenses in upcoming quarterly earnings calls as a signal of broader employer strategy.
Congressional action on drug pricing remains uncertain, with recent negotiation provisions facing legal challenges and industry opposition. Any changes to federal healthcare policy could alter the trajectory of employer costs heading into 2027 negotiations.